Get the Stockscreener App
4.07
0.74%
0.03
After Hours:
4.07
Sonoma Pharmaceuticals Inc stock is traded at $4.07, with a volume of 28,742.
It is up +0.74% in the last 24 hours and down -8.95% over the past month.
Sonoma Pharmaceuticals Inc is a specialty pharmaceutical company operating in the United States. It is engaged in identifying, developing, and commercializing differentiated therapies for patients living with chronic skin conditions. The company focuses on the development and commercialization of therapeutic solutions in medical dermatology to treat skin conditions, such as acne, atopic dermatitis, and scarring. The key products of the company are Celacyn, Ceramax Skin Barrier Cream, Mondoxyne, Alevicyn, SebuDerm, Microcyn, and Microcyn which are available for various skin treatments such as scars, itchy skin, minor skin irritations, rashes, and others. The company derives revenue from the sale of products in the United States, Latin America, Europe, Asia, and other countries.
See More
Previous Close:
$4.04
Open:
$4.01
24h Volume:
28,742
Relative Volume:
0.02
Market Cap:
$6.69M
Revenue:
$12.31M
Net Income/Loss:
$-5.08M
P/E Ratio:
-4.3298
EPS:
-0.94
Net Cash Flow:
$-5.20M
1W Performance:
-7.50%
1M Performance:
-8.95%
6M Performance:
+77.73%
1Y Performance:
+31.08%
1-Day Range:
$3.91
$4.25
1-Week Range:
$3.91
$4.4499
52-Week Range:
$1.75
$6.9199
Sonoma Pharmaceuticals Inc Stock (SNOA) Company Profile
Name
Sonoma Pharmaceuticals Inc
Sector
Phone
800-759-9305
Address
5445 CONESTOGA COURT, SUITE 150, BOULDER, CA
Compare SNOA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SNOA
Sonoma Pharmaceuticals Inc
|
4.07 | 6.67M | 12.31M | -5.08M | -5.20M | -0.94 |
|
ZTS
Zoetis Inc
|
142.26 | 62.54B | 9.39B | 2.62B | 2.22B | 5.8121 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.72 | 43.30B | 29.96B | 957.25M | 4.77B | 0.2956 |
|
HLN
Haleon Plc Adr
|
9.08 | 40.08B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
20.02 | 22.98B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
440.06 | 19.90B | 3.08B | 1.24B | 1.07B | 25.61 |
Sonoma Pharmaceuticals Inc Stock (SNOA) Latest News
Is Sonoma Pharmaceuticals Inc. stock a buy for dividend growthWeekly Profit Summary & Safe Capital Investment Plans - newser.com
Is Sonoma Pharmaceuticals Inc. stock in correction or buying zonePortfolio Gains Report & Daily Stock Trend Reports - newser.com
Analyzing net buyer seller activity in Sonoma Pharmaceuticals Inc.Portfolio Update Report & Weekly High Potential Stock Alerts - newser.com
Will Sonoma Pharmaceuticals Inc. stock attract more institutional investors2025 Dividend Review & Growth-Oriented Investment Plans - newser.com
Sonoma Pharmaceuticals Inc. stock trendline breakdown2025 Big Picture & High Win Rate Trade Alerts - newser.com
Can Sonoma Pharmaceuticals Inc. stock reach $100 price targetQuarterly Portfolio Report & Reliable Breakout Forecasts - newser.com
Is Sonoma Pharmaceuticals Inc. (O8Z) stock trading at attractive multiplesJuly 2025 Sector Moves & Reliable Breakout Forecasts - newser.com
What analysts say about Sonoma Pharmaceuticals Inc stockGeopolitical Risk Analysis & Exceptional Return Stocks - earlytimes.in
Why Sonoma Pharmaceuticals Inc. (O8Z) stock is favored by hedge fundsTrade Entry Report & Risk Managed Investment Strategies - newser.com
Sonoma Pharmaceuticals Inc. recovery potential after sell off2025 Price Momentum & Risk Controlled Daily Trade Plans - newser.com
Using RSI to spot recovery in Sonoma Pharmaceuticals Inc.2025 Key Lessons & Weekly Watchlist for Hot Stocks - newser.com
Is Sonoma Pharmaceuticals Inc. stock attractive for long term wealth buildingEarnings Summary Report & Intraday High Probability Setup Alerts - newser.com
Will Sonoma Pharmaceuticals Inc. rebound enough to break even2025 Price Momentum & Community Driven Trade Alerts - newser.com
Analyzing Sonoma Pharmaceuticals Inc. with risk reward ratio chartsEarnings Beat & Technical Pattern Alert System - newser.com
Tools to assess Sonoma Pharmaceuticals Inc.’s risk profileJuly 2025 Action & Risk Managed Trade Strategies - newser.com
Real time scanner hits for Sonoma Pharmaceuticals Inc. explainedRate Hike & AI Powered Buy and Sell Recommendations - newser.com
How Sonoma Pharmaceuticals Inc. stock performs in interest rate cycles2025 Trading Recap & AI Enhanced Trading Signals - newser.com
Sonoma Pharmaceuticals’ (SNOA) Sell (D-) Rating Reiterated at Weiss Ratings - Defense World
How institutional ownership impacts Sonoma Pharmaceuticals Inc. stockGold Moves & Short-Term Trading Alerts - newser.com
Sonoma Pharmaceuticals (SNOA) Expands Reach with FDA Cosmetic Re - GuruFocus
Sonoma Pharmaceuticals registers under FDA’s cosmetics act - Investing.com
Sonoma Pharmaceuticals Expands Market Reach with FDA Cosmetic Product Facility Registration and Microcyn-Based Cosmetic Product Listing Under MoCRA - ACCESS Newswire
Nearly $40B U.S. skin care market: Sonoma Pharma registers facility, lists Microcyn spray under MoCRA - Stock Titan
Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) Sees Large Drop in Short Interest - Defense World
Real time alert setup for Sonoma Pharmaceuticals Inc. performance2025 Short Interest & Real-Time Volume Triggers - newser.com
Is Sonoma Pharmaceuticals Inc. showing signs of accumulationBuy Signal & Breakout Confirmation Trade Signals - newser.com
Analyzing drawdowns of Sonoma Pharmaceuticals Inc. with statistical toolsWeekly Trend Summary & Risk Controlled Daily Trade Plans - newser.com
Can Sonoma Pharmaceuticals Inc. (O8Z) stock sustain double digit ROEQuarterly Trade Review & Real-Time Volume Surge Alerts - newser.com
Using fundamentals and technicals on Sonoma Pharmaceuticals Inc.July 2025 Outlook & Precise Trade Entry Recommendations - newser.com
Developing predictive dashboards with Sonoma Pharmaceuticals Inc. dataJuly 2025 Action & Weekly Return Optimization Alerts - newser.com
Sonoma Pharmaceuticals Highlights Growth in Healthcare Sector - TipRanks
Sonoma Pharmaceuticals Inc Stock (SNOA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.42%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):